BRL-15,572
BRL-15,572 is an experimental antidepressant drug that acts as a selective 5-HT1A receptor partial agonist. It was developed by GlaxoSmithKline in the 1990s. The compound has been studied for its potential to treat depression and anxiety disorders.
Pharmacology[edit | edit source]
BRL-15,572 functions primarily as a selective 5-HT1A receptor partial agonist. The 5-HT1A receptor is a subtype of the serotonin receptor that is implicated in the regulation of mood and anxiety. By modulating the activity of this receptor, BRL-15,572 may help to alleviate symptoms of depression and anxiety.
Research[edit | edit source]
Preclinical studies have shown that BRL-15,572 has potential antidepressant and anxiolytic effects. However, its development has not progressed to clinical trials, and it remains an experimental compound. Further research is needed to fully understand its efficacy and safety profile.
See also[edit | edit source]
References[edit | edit source]
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD
